Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Contineum-J&J drug fails to improve vision in phase 2 MS trial
The Johnson & Johnson-partnered asset failed to trigger any significant change in vision acuity for MS patients.
Gabrielle Masson
Nov 20, 2025 5:26pm
Pfizer details phase 3 data for mRNA flu vaccine
Nov 20, 2025 11:25am
Merck's HIV combo matches Gilead's Biktarvy in phase 3 test
Nov 19, 2025 8:10am
Vanda tackles Wegovy-driven vomiting, sparking race to ph. 3
Nov 18, 2025 10:44am
Roche's oral SERD hits goal in adjuvant breast cancer phase 3
Nov 18, 2025 9:16am
Nuvalent races to FDA to challenge Pfizer for lung cancer market
Nov 17, 2025 7:45am